Phase II/III Clinical Trial of TO-203 -Efficacy and Safety Trial in Patients with HDM-induced Asthma-

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221805

Enrollment

900

Registered

2012-05-29

Start date

2012-05-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HDM-induced asthma

Interventions

investigational material(s) Generic name etc : TO-203 INN of investigational material : Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) HDM-specific IgE antibodies >= Class 3 (2) Positive HDM-allergen scratch or prick test (3) Asthmatic symptoms were treated with ICS (4) Dicumented reversible airway obstruction (5) FEV1 > 70% of the predicted value

Exclusion criteria

Exclusion criteria: (1) Patients who have perennial symptoms of asthma or rhinitis due to regular exposure to antigens (excluding HDM). (2) Patients who received immunotherapy with HDM allergen-containing products (e.g., house dust) for at least 1 month during 5 years before the first day of observation. (3) Patients who are on immunotherapy other than HDM allergen-containing products on the first day of observation. (4) Patients with a history of serious adverse drug reactions due to immunotherapy. (5) Patients who were hospitalized due to worsening of asthma within 3 months before the first day of observation.

Design outcomes

Primary

Measure	Time frame
Efficacy, Dose dependency, Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026